Advanced search    

Search: authors:"Kevork M Peltekian"

14 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Improving Access to Transient Elastography in Canada Will Need More Than Evidence-Based Guidelines and Technical Health Assessment

Can J Gastroenterol Hepatol Improving access to transient elastography in Canada will need more than evidence-based guidelines and technical health assessment Kevork M Peltekian FRCPC 0 0

Improving Access to Transient Elastography in Canada Will Need More Than Evidence-Based Guidelines and Technical Health Assessment

Can J Gastroenterol Hepatol Improving access to transient elastography in Canada will need more than evidence-based guidelines and technical health assessment Kevork M Peltekian FRCPC 0 0

Finally... Real Utility Scores for Hepatitis C Patients!

Can J Gastroenterol Finally...real utility scores for hepatitis C patients! Kevork M Peltekian FRCPC ARTICLE SUMMARY Chong and colleagues (1) used gold-standard methods to assess health-state ... previously conducted cost effectiveness studies of HCV therapy, especially here in Canada. Kevork M Peltekian MD FRCPC Division of Gastroenterology, Dalhousie University Atlantic Liver Transplant Program

With All the New Treatment Regimens, Complete Elimination of Hepatitis C Virus in Canada Is a Possibility! But When Will Canadians Have Access to These Drugs?

Care & Endoscopy, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia Correspondence: Dr Kevork M Peltekian, Atlantic Hepatology Services Inc, PO Box 60010, Halifax ... Can J Gastroenterol Hepatol with all the new treatment regimens, complete elimination of hepatitis c virus in canada is a possibility! But when will canadians have access to these drugs? Kevork M

Improving Access to Transient Elastography in Canada Will Need More Than Evidence-Based Guidelines and Technical Health Assessment

Can J Gastroenterol Hepatol Improving access to transient elastography in Canada will need more than evidence-based guidelines and technical health assessment Kevork M Peltekian FRCPC 0 0

Finally... Real Utility Scores for Hepatitis C Patients!

Can J Gastroenterol Finally...real utility scores for hepatitis C patients! Kevork M Peltekian FRCPC ARTICLE SUMMARY Chong and colleagues (1) used gold-standard methods to assess health-state ... previously conducted cost effectiveness studies of HCV therapy, especially here in Canada. Kevork M Peltekian MD FRCPC Division of Gastroenterology, Dalhousie University Atlantic Liver Transplant Program

With All the New Treatment Regimens, Complete Elimination of Hepatitis C Virus in Canada Is a Possibility! But When Will Canadians Have Access to These Drugs?

Care & Endoscopy, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia Correspondence: Dr Kevork M Peltekian, Atlantic Hepatology Services Inc, PO Box 60010, Halifax ... Can J Gastroenterol Hepatol with all the new treatment regimens, complete elimination of hepatitis c virus in canada is a possibility! But when will canadians have access to these drugs? Kevork M

Gut Toxicity of 5-ASA?

de Crohn proximale. 5-ASA; Crohn's disease; Duodenitis; Gastritis; Peptic ulceration - DESMOND JLEDDIN, MO, MRC Pl, MSC, FRCPC, KEVORK M PELTEKIAN, MD, FRC PC T cared in the presence of active HE

Complementary and Alternative Medicine Use by Patients Chronically Infected with Hepatitis C Virus

, Departments of Medicine, Dalhousie University and the Capital District Health Authority, Halifax, Nova Scotia; 2Rockyview General Hospital, Calgary, Alberta Correspondence and reprints: Dr Kevork M Peltekian ... Can J Gastroenterol Complementary and alternative medicine use by patients chronically infected with hepatitis C virus Colin P White 0 Gerilynn Hirsch NP 0 Sunil Patel 0 Fatin Adams 0 Kevork M

Complementary and Alternative Medicine Use by Patients Chronically Infected with Hepatitis C Virus

, Departments of Medicine, Dalhousie University and the Capital District Health Authority, Halifax, Nova Scotia; 2Rockyview General Hospital, Calgary, Alberta Correspondence and reprints: Dr Kevork M Peltekian ... Can J Gastroenterol Complementary and alternative medicine use by patients chronically infected with hepatitis C virus Colin P White 0 Gerilynn Hirsch NP 0 Sunil Patel 0 Fatin Adams 0 Kevork M

Open Trial of Cyclosporine in Patients with Severe Active Crohn's Disease Refractory to Conventional Therapy

Fifteen patients with severe active Crohn's disease, refractory to conventional therapy, were given a 16 week course of cyclosporine ar an initial oral daily dose of 10 mg/kg, adjusted to maintain cyclosporine scrum trough levels between 100 and 200 ng/ml. Five patients withdrew early because of side effects, poor absorption or noncompliance. T he remaining 10 patients all...

Survival after Liver Transplantation for Hepatitis C Is Unchanged over Two Decades in Canada

Marotta FRCPC Andrew Mason Kevork M Peltekian Eberhard Renner Eric M Yoshida MHSc FRCPC FACP Allograft failure secondary to recurrence of hepatitis C virus (HCV) infection is the most common cause of

Survival after Liver Transplantation for Hepatitis C Is Unchanged over Two Decades in Canada

Marotta FRCPC Andrew Mason Kevork M Peltekian Eberhard Renner Eric M Yoshida MHSc FRCPC FACP Allograft failure secondary to recurrence of hepatitis C virus (HCV) infection is the most common cause of

Recurrent Hepatitis C Post-Transplantation: Where Are We Now and Where Do We Go From Here? A Report from the Canadian Transplant Hepatology Workshop

Burak FRCPC MSc Marc Desch?nes FRCPC Les Lilly Denis Marleau Paul Marotta FRCPC Andrew Mason MBBS MRCPI Kevork M Peltekian FRCPC Eberhard L Renner Eric M Yoshida MHSc FRCPC for the Canadian